Day: August 9, 2021

Umicore: Interim dividend to be paid on 24 AugustAs announced on 30 July 2021, the Supervisory Board approved a gross interim dividend of € 0.25 per share (ISIN BE0974320526). This represents a dividend of € 0.175 net of withholding tax. The interim dividend will be paid out on Tuesday 24 August 2021. The share will be traded ex coupon as from Friday 20 August 2021. The record date will be Monday 23 August 2021. The System Paying Agent designated for the payment of the 2021 interim dividend is: KBC Bank                                                                 Havenlaan / Avenue du Port, 2                                   1080   Brussels More information can be found on:                              http://www.umicore.com/en/investors/share-information/dividend-information/For more information Investor Relations Saskia Dheedene ...

Falcon Oil & Gas Ltd.(“Falcon”) Amungee NW-1H 2021 Work Programme – Beetaloo Sub-Basin 09 August 2021 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce the commencement of production testing operations at Amungee NW-1H (“Amungee”) in the Beetaloo Sub-Basin, Northern Territory, Australia with our joint venture partner, Origin Energy B2 Pty Ltd., a wholly owned subsidiary of Origin Energy Limited (“Origin”). On-site operations at Amungee have begun with all equipment on site and preparatory works complete. A production test is now underway to determine whether all eleven frack stages contributed to the initial extended production test (“EPT”) in 2016. Background and details of the 2016/2017 results at AmungeeThe Amungee horizontal well was drilled to 1,100 meters 11 frack stages were executed along the...

Vaccine was well tolerated across all dose groups with no observed difference in adverse event profile after first and second vaccination Strong booster effect demonstrated after second vaccination with antibody titers above levels detected in humans after COVID-19 disease and neutralization titers significantly above those reported for currently approved SARS-CoV-2 vaccines Strong cross neutralization of SARS-CoV2 variants, including the Delta variantCOPENHAGEN, Denmark, August 9, 2021 – Bavarian Nordic A/S (OMX: BAVA) today reported initial results from the first-in-human trial of ABNCoV2, led by the PREVENT-nCoV consortium. The Phase 1/2 dose-escalation trial enrolled 45 healthy SARS-CoV-2-naïve adult volunteers at the Radboud University Medical Centre in the Netherlands, who received two doses (dose ranges from 6-70 μg) of ABNCoV2,...

SIKA ACQUIRES LEADING BUILDING FINISHING MORTAR COMPANY IN MEXICO Sika acquires Bexel Internacional S.A. de C.V., a leading manufacturer of tile adhesives and stuccos in Mexico. The acquisition strengthens Sika’s position in the large, fast-growing Mexican mortar market and significantly extends its manufacturing footprint. In 2020, the acquired company generated sales of CHF 35 million. Bexel is a family-owned, well-run business which has successfully built up a strong position in the Mexican Building Finishing mortars market. The company enjoys an excellent reputation through its well-known brand and has a strong presence in the distribution channel, mostly focusing on home centers and builders’ merchants. Bexel operates five strategically located production plants which perfectly complement Sika’s existing geographical footprint and...

Pivotal phase III POLARIX trial comparing Polivy in combination with chemotherapy regimen R-CHP versus the standard of care R-CHOP in treatment of first-line diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of investigator-assessed progression-free survival Prolonging survival without disease advancement could be transformative for newly diagnosed DLBCL patients as currently 40% of patients relapse after disease progression Data will be submitted to health authorities globally as soon as possible and presented at an upcoming medical meetingBasel, 9 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan...

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — via InvestorWire — MedSmart Group Inc. (OTC:MSGP) (“MSGP” or the “Company”), following the recent announcement to acquire Milanion Limited (“Milanion”), today shared news that Milanion has strategically positioned itself to take a share of the Eastern European defense market. The company is making inroads into Ukraine with the signing of an MOU with Ukrainian Armor LLC (“Ukrainian Armor”) for distribution rights to the AGEMA UGV. Interest in the AGEMA UGV has surged since the vehicle was recently showcased at the Arms and Security 21 exhibition in Kyiv. The ultra-versatile AGEMA is a modular, agile, affordable unmanned ground vehicle (UGV) equipped with proven world-class technology and performance. It is designed to support a range of missions in a variety of sectors including defense,...

Oslo, 9 August 2021 – DNO ASA, the Norwegian oil and gas operator, today announced that the Gomez exploration well on the PL006C license offshore Norway was spudded this weekend and will be drilled to a depth of approximately 3,300 meters below sea level, targeting Paleocene age formations. DNO Norge AS holds a 65 percent operated interest in the license with the balance held by Aker BP. Aker BP originally had a 15 percent interest but recently acquired another 20 percent interest in PL006C from DNO under a swap agreement in which DNO picked up a 25 percent participating interest in PL1085 (Tanumåsen) and increased its share from 20 to 30 percent in PL906 (Mugnetind), diversifying its position in the southern North Sea. The swap is subject to government approval. The Borgland Dolphin rig arrived on location on 7 August following the successful...

Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in pre-clinical models with the potential to overcome inflammatory side effectsOngoing research discovery alliance with AbbVie in ophthalmology to continueZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LRMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today the receipt of notification from its partner, AbbVie Inc., regarding its termination of the license and collaboration agreement for the investigational drug abicipar pegol for the treatment of neovascular age-related macular degeneration...

Innofactor Plc press release, on August 9, 2021, at 7:00 Finnish time Effective from August 9, 2021, Innofactor has appointed Jarno Limnéll, Professor of Practice, Cybersecurity at Aalto University, as head of the company’s new Cybersecurity Unit. Together with HUS Helsinki University Hospital, KPMG and Microsoft, Innofactor is organizing a virtual media event today, at 12:00 noon, on the topic of cybersecurity in Finnish organizations. Event participants will have the opportunity to ask Limnéll and other speakers questions about cybersecurity in Finland. Effective from August 9, 2021, Innofactor has appointed Jarno Limnéll, Professor of Practice, Cybersecurity at Aalto University, as head of the company’s new Cybersecurity Unit. He will join Innofactor’s Finnish leadership team and be responsible for the business of the unit that...

SANTA MONICA, Calif., Aug. 08, 2021 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of  $20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the...